Nifuroxazide has a particularly strong effect at reducing the viability of MM cells overexpressing CKS1B, which is associated with poor prognosis in MM patients and which is associated with enhanced STAT3 activation [4]. Here, CKS1B is linked to Miyoshi myopathy.